Pharmaceutical parallel trade in Europe: Stakeholder and competition effects

Economic Policy

Volumn 20, Issue 44, 2005, Pages 751-798

  Kanavos, Panos ^a   Costa Font, Joan ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION (ECONOMICS); ECONOMETRICS; ECONOMIC POLICY; EMPIRICAL ANALYSIS; PRICE DYNAMICS; STAKEHOLDER; STATISTICAL DATA; TRADE;

EURASIA; EUROPE; EUROPEAN UNION;

EID: 33748165631     PISSN: 02664658     EISSN: 14680327     Source Type: Journal    
DOI: 10.1111/j.1468-0327.2005.00150.x     Document Type: Article

References (76)

1. Abbott, F.M. (1998). 'First report (final) to the Committee on International Trade Law of the International Law Association on the subject of parallel importation', Journal of International Economic Law, 1, 607-36.
2. Ahmadi, R. and B.R. Yang (2000). 'Parallel imports: Challenges from unauthorised distribution channels', Marketing Science, 19(3), 279-94.
3. Baltagi, B.H. (1995). Econometric Analysis of Panel Data, John Wiley and Sons, New York.
4. Barfield, C.E. and M.A. Groombridge (1999). 'Parallel trade in pharmaceuticals: Economic development and health policy', Unpublished draft no. 1 (February 4), Washington, DC: American Enterprise Institute.
5. Calcott, P. (1999). 'Demand inducement as cheap talk', Health Economics 8(8), 721-33.
6. Carlsen, F. and J. Grytten (2000). 'Consumer satisfaction and supplier induced demand', Journal of Health Economics, 19(5), 731-53.
7. Caves, R.E., M. D. Whinston and M.A. Huwitz (1991). 'Patent expiration, entry and competition in the US pharmaceutical industry', Brookings Papers on Economic Activity -Microeconomics, 1-66.
8. Costa-Font, J. and Puig-Junoy, J. (2004). 'Regulatory ambivalence and the limitations of pharmaceutical policy in Spain', Faculty of Economics and Business, Working Paper No 762, Universitat Pompeu Fabra, Barcelona.
9. Danzon, P. (1998). 'The economics of parallel trade', Pharmacoeconomics, 13, 293-304.
10. De Jaegher, K. and M. Jegers (2000). 'A model of physician behaviour with demand inducement', Journal of Health Economics, 19(2), 231-58.
11. European Court of Justice (1996), ECJ Cases C-267/95 and C-268/95 Merck and Others v. Primecrown and Others and Beecham Group v Europharm of Worthing, judgment of 5 December.
12. European Court of Justice (1997), Joint Cases C-427/93, C-429/93, C-436/ 93 Bristol-Myers Squibb v. Paranova [1997]ESR 102.
13. European Court of Justice (1999), ECJ Case C-443/99 Merck, Sharp & Dohme GmbH v. Paranova Pharmazeutika Handels GmbH.
14. European Court of Justice (2000a), ECJ Case T-41/96 Bayer AG v. Commission of the European Communities, judgment of 26 October.
15. European Court of Justice (2000b), ECJ Case C-143/00 Boehringer Ingelheim GmbH, Glaxo Group Ltd and others v. Dowelhurst Ltd and Swingward Ltd.
16. European Court of Justice (2002), ECJ Case C-433/00 Aventis Pharma Deutschland GmbH v. Kohlpharma GmbH and MTK Pharma Vertrieb-GmbH, Comment of 19 September.
17. European Court of Justice (2003), 'Common origin not prerequisite for parallel trade', Opinion, ECJ case C-112/02, Kohlpharma GmbH vs. Federal Republic of Germany, 12 September.
18. European Court of Justice (2004), Judgment of the Court of Justice in Joined Cases C-2/01 P and C-3/01 P: Bundesverband der Arzneimittel-Importeure and Commission of the European Communities v Bayer AG; Press Release No. 01/04, http://curia.eu.int/jurisp/cgi-bin/form.pl?lang=en&Submit= Submit&docrequire=alldocs&numaff=C-2%2F01+P&datefs= &datefe=&nomusuel=&domaine=&mots=&resmax=100
19. Frank, R.G. and D.S. Salkever (1992). 'Pricing, patent loss and the market for pharmaceuticals', Southern Economic Journal, 59 (October), 165-79.
20. Gallini, N. and A. Hollis (1999). 'A contractual approach to the gray market', International Review of Law and Economics, 19, 1-21.
21. Ganslandt, M. and K.E. Maskus (2001). 'Parallel imports of pharmaceutical products in the European Union', Working Paper No. 546, The Research Institute of Industrial Economics.
22. Ganslandt, M. and K.E. Maskus (2004). 'Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union', Journal of Health Economics, 23, 1035-57.
23. Gardner, L.B., H. S. Javitz and B.P. Recine (1997). 'Pharmaceutical use and cost among insured elderly', Agency for Health Care Policy and Research, March.
24. Grabowski, H. and J. Vernon (1992). 'Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act', Journal of Law and Economics, 35, 331-50.
25. Grootendorst, P.V., B. J. O'Brien and G.M. Anderson (1997). 'On becoming 65 in Ontario: Effects of drug plan eligibility on use of prescription medicines', Medical Care, 35, 386-98.
26. Grytten, J. and R. Sorensen (2001). 'Type of contract and supplier-induced demand for primary physicians in Norway', Journal of Health Economics, 20(3), 379-93.
27. Hausman, J.A. and J.K. MacKie-Mason (1988). 'Price discrimination and patent policy', RAND Journal of Economics, 19, 253-65.
28. Hellenic Republic (2001a), Establishment of a database for parallel exports by wholesalers, Hellenic National Drug Organisation (Circular), Athens, 3 October.
29. Hellenic Republic (2001b), Ensuring adequate supply of pharmaceutical products in the Greek market, Hellenic National Drug Organisation (Circular), Athens, 27 November.
30. Hudson, J. (1992). 'Pricing dynamics in the pharmaceutical industry', Applied Economics, 24, 103-12.
31. Hughes, D. and A. McGuire (1995). 'Patient charges and the utilisation of NHS prescription medicines: Some estimates using a cointegration procedure', Health Economics, 4(3), 213-20.
32. Intercontinental Medical Statistics (IMS) (2002), Acts 2002, IMS Health Quality Assurance.
33. Johnson, R.E., M. J. Goodman, M.C. Hornbrook and M.B. Eldredge (1997). 'The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members', HSR: Health Service Research 32, 103-22.
34. Jelovac, I. and C. Bordoy (2005). 'Pricing and welfare implications of parallel imports in the pharmaceutical industry', International Journal of Health Care Finance and Economics, 5, 5-21.
35. Kanavos, P. (1998). 'Single European Market and Monetary Union: Macroeconomic implications for pharmaceutical spending', Pharmacoeconomics, 13(1 Pt 1), 9-20.
36. Kanavos, P. (2000). 'The single market for pharmaceuticals in the European Union in light of European Court of Justice Rulings', Pharmacoeconomics, 18(6), 523-32.
37. Kanavos, P. (2002). Pharmaceutical Pricing and Reimbursement in Europe, PJB Publications, Richmond, Surrey.
38. Kanavos, P. and M. Gemmill (2005). Pharmaceutical Pricing and Reimbursement in Europe, Informa Publishing, London.
39. Kanavos, P. and U. Reinhardt (2003). 'Reference pricing for drugs: Is it the right solution for the US?' Health Affairs, 22(3), 16-30.
40. Kanavos, P., Gross, D. and Taylor, D. (2005). 'Parallel trading in medicines: Europe's experience and its implications for commercial drug importation in the United States', American Association for Retired Persons (AARP), AARP Public Policy Institute paper No. 2005-07, Washington, DC.
41. Kenny, P. and P. McNutt (1999). 'Competition, parallel imports and trademark exhaustion: Two wrongs from a trademark right', Discussion Paper, Competition Authority, UK.
42. Kingdom of Spain (2003). Ministerio de Sanidad y Consumo, Decreto ley 725-2003, modifying article 10 of the medicines law (Requirement by wholesalers to submit reports revealing the destination of the products they acquire from suppliers), Madrid, May.
43. Knox, D. and M. Richardson (2003). 'Trade policy and parallel imports', European Journal of Political Economy, 19(1), 133-51.
44. Kontozamanis, V., E. Mantzouneas and C. Stoforos (2003). 'An overview of the Greek pharmaceutical market', European Journal of Health Economics, 4, 327-33.
45. Krugman, P.R. and M. Obstfeld (1991). International Economics: Theory and Policy, Harper Collins, 2nd edn.
46. Lavers, R.J. (1989). 'Prescription charges, the demand for prescriptions and morbidity', Applied Economics, 21, 1043-52.
47. Leibowitz, A., W. Manning and J. Newhouse (1985). 'The demand for prescription drugs as a function of cost-sharing', Social Science and Medicine, 21(10), 1063-69.
48. Linnosmaa, I., T. Karhunen and I. Vohlonen (2003). 'Parallel importation of pharmaceuticals in Finland: Effects on markets and expenditures', Pharmaceutical Development and Regulation, 1, 67-74.
49. Macarthur, D. (2003). Parallel Trade with Medicines in Europe: The Facts, http://www.eaepc.org, accessed and downloaded 12 September.
50. Malueg, D. and M. Schwartz (1994). 'Parallel imports, demand dispersion and international price discrimination', Journal of International Economics, 37, 187-96.
51. Maskus, K.E. (2001). 'Parallel imports in pharmaceuticals: Implications for competition and prices in developing countries', Final Report to the World Intellectual Property Organisation, April.
52. Maskus, K.E. and Chen, Y. (2002). 'Parallel imports in a model of vertical distribution: Theory, evidence, and policy', Pacific Economic Review, 7, 319-34.
53. Maskus, K.E. and Chen, Y. (2004). 'Vertical price control and parallel imports: Theory and evidence', Review of International Economics, 12(4), 551-57.
54. Mortimer, R. (1997). 'Demand for prescription drugs: The effects of managed care pharmacy benefits', Working Paper, Department of Economics, University of California, Berkeley.
55. Mossialos, E., A. Dixon, J. Figueras and J. Kutzin (eds.) (2002). Funding Health Care: Options for Europe. Open University Press, Buckingham.
56. Mossialos, E. and J. Legrand (eds.) (1999). Health Care and Cost Containment in the European Union, Ashgate, Aldershot.
57. Mossialos, E.A., Mrazek, M. and T. Walley (eds.) (2004). Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Open University Press, Bucks.
58. Pecorino, P. (2002). 'Should the US allow prescription drugs reimports from Canada?' Journal of Health Economics, 21, 699-708.
59. O'Brien, B. (1989). 'The effect of patient charges on the utilisation of prescription benefits', Journal of Health Economics, 8, 109-32.
60. Persson, U., A. Anell and M. Persson (2003). Swedish Institute of Health Economics, Abstract No. 763.
61. Philipson, A. (2001). 'Guide to the concept and practical application of articles 28-30 EC', Commission of the European Communities, DG Enterprise, Brussels, January.
62. Rey, P. (2003). 'The impact of parallel trade on prescription medicines', mimeo.
63. Richardson, M. (2002). 'An elementary proposition concerning parallel imports', Journal of International Economics, 56(1), 233-45.
64. Rose, A. (2000). 'National money, one market: Estimating the effect of common currencies on trade', Economic Policy, 15(30), 7-46.
65. Rose, A. and E.C. Wincoop (2001). 'One national money as a barrier to trade: The real case for monetary union', American Economic Review, 91(2), 386-90.
66. Ryan, M. and S. Birch (1991). 'Charging for health care: Evidence on the utilisation of NHS prescribed drugs', Social Science and Medicine, 33, 681-87.
67. Selke, G. (1994). 'Reference pricing systems in the European Community', in E. Mossialos, C. Ranos and B. Abel-Smith (eds.), Cost Containment, Pricing and Financing of Pharmaceuticals in the European Community: The Policy-Makers'View, LSE Health and Pharmetrica, Athens.
68. Smith, S. and S. Watson (1990). 'Modeling the effect of prescription charge rises', Fiscal Studies, 11, 75-91.
69. Sorensen, R.J. and J. Grytten (1999). 'Competition and supplier-induced demand in a health care system with fixed fees', Health Economics, 8(6), 497-508.
70. Tirole, J. (1989). The Theory of Industrial Organisation, MIT Press, Cambridge.
71. To Vima (2002). Pharmaceutical Product Shortages in the Greek Market, 2001-2002, 10 April 2002, based on a communication with the National Pharmacists' Association.
72. Valletti, T.M. and S. Szymanski (2003). 'Parallel trade, international exhaustion and intellectual property rights: A welfare analysis', CEPR Discussion Paper 5022, London.
73. Varian, H.R. (1989a). Intermediate Microeconomics, Norton, 2nd edn.
74. Varian, H.R. (1989b). 'Price discrimination', in R. Schmalensee and R. Willig (eds.), Handbook of Industrial Organization. North-Holland Press, Amsterdam.
75. Van de Voorde, C. E. Van Doorslaer and E. Schokkaert (2001). 'Effects of cost sharing on physician utilization under favourable conditions for supplier-induced demand', Health Economics, 10(5), 457-71.
76. West, P. and J. Mahon (2003). Benefits to Payers and Patients from Parallel Trade, York Health Economics Consortium, York, May, http://www.yhec.co.uk.